A Major Anti-Inflammatory Heart Drug Trial Failed, Testing a Leading Theory About Artery Disease

Novo Nordisk’s ziltivekimab lowered inflammation but did not reduce heart attacks, strokes, or cardiovascular deaths in a 6,300-patient trial.

Have A Referral?